Juno Therapeutics (JUNO) Shares are Up 3.81%

Juno Therapeutics (JUNO) : Traders are bullish on Juno Therapeutics (JUNO) as it has outperformed the S&P 500 by a wide margin of 10.67% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 3.76%, relative to the S&P 500. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 3.81% in the last 1 week, and is up 11.81% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.

The stock has recorded a 20-day Moving Average of 7.59% and the 50-Day Moving Average is 9.79%. Juno Therapeutics (NASDAQ:JUNO): stock turned positive on Friday. Though the stock opened at $31.6, the bulls momentum made the stock top out at $33.18 level for the day. The stock recorded a low of $31.51 and closed the trading day at $32.66, in the green by 3.29%. The total traded volume for the day was 963,419. The stock had closed at $31.62 in the previous days trading.


The company Insiders own 15.26% of Juno Therapeutics shares according to the proxy statements. In the past twelve weeks, the net percent change held by company insiders has changed by -2.09% . Institutional Investors own 58.25% of Juno Therapeutics shares. During last six month period, the net percent change held by insiders has seen a change of -4.39%. Also, Barclays initiates coverage on Juno Therapeutics (NASDAQ:JUNO). Barclays has a Equal-weight rating on the shares. As per the latest report, the brokerage house announces the price target to $48 per share. The rating by the firm was issued on July 6, 2016.

Juno Therapeutics, Inc. (Juno) is a biopharmaceutical company. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells. Junos product candidates, JCAR015, JCAR017 and JCAR014, utilize CAR technology to target CD19, a protein expressed on the surface of various B cell leukemias and lymphomas. Junos other product candidates include JCAR018: CD22, JCAR023: L1CAM (CD171), JCAR020: MUC-16 / IL-12, ROR-1 and JTCR016: WT-1. JCAR015 is in Phase I open label clinical trial stage for patients with acute lymphoblastic leukemia (r/r ALL). JCAR017 is in Phase I/II trial for patients with pediatric r/r ALL. JCAR014 is in Phase I/II trial as a treatment for various B cell malignancies in patients. JTRC016 is in Phase I/II clinical trial for the treatment of AML, myelodysplasic syndrome and chronic myeloid leukemia.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *